Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04639518
Other study ID # 18.09.INF
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 10, 2020
Est. completion date October 2025

Study information

Verified date March 2023
Source Société des Produits Nestlé (SPN)
Contact Amelie L Goyer, PhD
Phone 0041 21 785 8939
Email amelie.goyer1@rd.nestle.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label trial consisting of two sub-studies to be conducted sequentially with the purpose of evaluating the safety and suitability of a two feeding systems in pre-term infants (one containing HMOs and one without HMOs).


Description:

This is a multi-center, open-label trial to be conducted in up to 70 pre-term infants in order to evaluate the safety and suitability of two feeding systems as they would typically be used in the neonatal care unit. Growth (in comparison to recommended growth goals), feeding tolerance, biochemical parameters, and adverse event reporting will be evaluated. The two feeding systems will be tested in two sub-studies to be conducted sequentially: sub-study 1 will evaluate a two-staged feeding system with HMOs in up to 35 pre-term infants; sub-study 2 will evaluate a two-staged feeding system without HMOs in up to 35 pre-term infants. A follow up period from 12 to 24 months have been added to the study protocol, to assess the neurocognitive development of the subjects during this period.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date October 2025
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 10 Days
Eligibility Inclusion Criteria: 1. Written informed consent has been obtained from one or both parent(s) /legally acceptable representative (LAR) in accordance with local regulation. 2. Infants' birth weight =1500 g and AGA. 3. Infant's gestational age < 37 weeks. 4. Infant is clinically stable and does not have deteriorating respiratory function after birth. 5. Infant is eligible to start experimental formula after 24 hours of trophic feeding, but still within the first 10 days (=240 hours) of life. Exclusion Criteria: 1. Parent(s) not willing / not able to comply with the requirements of study protocol. 2. Infant is experiencing early onset sepsis. 3. Major congenital or chromosomal abnormality known to affect growth. 4. Liver failure. 5. Peri-/intra-ventricular haemorrhage (grade 3-4 in Papille classification). 6. Infant who has siblings with diagnosed allergies or intolerances to lactose or cow's milk. 7. Infant's participation in another interventional clinical trial. 8. Infant has already achieved FEF prior to enrolment, using the definition accepted by Neonatal Unit as per standard practice (150 mL/kg/day).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Preterm formulas with HMO
Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
Preterm formulas without HMO
Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.

Locations

Country Name City State
Poland Klinika Neonatologii, Szpital Uniwersyteck Bydgoszcz
Poland Klinika Chorob Dzieci, Uniwersytecki Szpital Dzieciecy Kraków
Serbia Clinical Center of Serbia Belgrad
Slovakia Univerzitna nemocnica Martin Martin
Slovakia Fakultna nemocnica s poliklinikou Nove Zamky Nove Zamky

Sponsors (1)

Lead Sponsor Collaborator
Société des Produits Nestlé (SPN)

Countries where clinical trial is conducted

Poland,  Serbia,  Slovakia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Growth Weight-adjusted weight gain (g/kg/day) From FEF Day 1 to when infant reaches 1800 g (on average between 4 to 6 weeks after birth) or hospital discharge (on average 7 weeks after birth), whichever comes earlier
Secondary Weight at other time points Changes in weight gain (g/day and g/kg/day) From Pre-FEF Day 1 to FEF Day 1, and then weekly from FEF Day 1 until hospital discharge (on average 7 weeks after birth), at 30- and 60-days PD, and at 12, 18, and 24 months
Secondary Other growth parameter (length) Change in length (cm/week) From Pre-FEF Day 1 to hospital discharge (on average 7 weeks after birth), at 30- and 60-days PD, and at 12, 18, and 24 months
Secondary Other growth parameter (head circumference) Change in head circumference (cm/week) From Pre-FEF Day 1 to hospital discharge (on average 7 weeks after birth), at 30- and 60-days PD, and at 12, 18, and 24 months
Secondary Anthropometric z-scores for weight, length and head circumference Corresponding z-scores and changes in z-scores expressed using Fenton growth chart will be analyzed From Pre-FEF Day 1 to hospital discharge (on average 7 weeks after birth), at 30- and 60-days PD, and at 12, 18, and 24 months
Secondary Feeding intake at neonatal unit Neonatal unit feeding questionnaire capturing timing, type, rate and amount of feeding (parenteral & enteral), gastric residual volumes, number of missed feedings Baseline + weekly over 3 consecutive days starting on pre-FEF Day1 + weekly over 3 consecutive days starting on FEF Day1 until Neonatal Unit Discharge (on average 7 weeks after birth)
Secondary Stool frequency at neonatal unit Stool frequency (range from 0-20 times a day) collected via neonatal unit questionnaire Weekly between FEF Day 1 and hospital discharge (on average 7 weeks after birth)
Secondary Stool consistency at neonatal unit Stool consistency (watery, mushy soft, runny, formed, hard) collected via neonatal unit questionnaire Weekly between FEF Day 1 and hospital discharge (on average 7 weeks after birth)
Secondary Bloody stools at neonatal unit Bloody stools (yes or no) collected via neonatal unit questionnaire Weekly between FEF Day 1 and hospital discharge (on average 7 weeks after birth)
Secondary GI symptoms at neonatal unit GI symptoms (incidence of abdominal distention, regurgitation, spitting and vomiting) collected via neonatal unit questionnaire Weekly between FEF Day 1 and hospital discharge (on average 7 weeks after birth)
Secondary Feeding intake after discharge Parent-reported 3-Day Intake Diary capturing the total number of bottles of formula and approximate volumes consumed per day 3 consecutive days just prior to the 30-day PD and 60-day PD visits
Secondary Stool frequency after discharge Stool frequency captured via parent-reported 3-Day Intake Diary 3 consecutive days just prior to the 30-day PD and 60-day PD visits
Secondary Stool consistency after discharge Stool frequency captured via parent-reported 3-Day Intake Diary 3 consecutive days just prior to the 30-day PD and 60-day PD visits
Secondary GI symptoms after discharge GI symptoms (such as presence of stomach ballooning, bloody stools, regurgitation, spitting-up and vomiting) captured via parent-reported 3-Day Intake Diary 3 consecutive days just prior to the 30-day PD and 60-day PD visits
Secondary GI-related behaviors after discharge GI-related behaviors (such as crying and sleep quality) captured via parent-reported 3-Day Intake Diary 3 consecutive days just prior to the 30-day PD and 60-day PD visits
Secondary Serum biomarkers for protein status Serum albumin and blood urea nitrogen (BUN) At Baseline (if possible), pre-FEF Day 1, then weekly pre-FEF Days 7, 14, etc. and FEF Day 1, then weekly on FEF Days 7, 14, 21, until Neonatal Unit Discharge, and at 60 days PD
Secondary Serum biomarkers for bone health Serum P, alkaline phosphatase, calcium and creatinine At Baseline (if possible), pre-FEF Day 1, then weekly pre-FEF Days 7, 14, etc. and FEF Day 1, then weekly on FEF Days 7, 14, 21, until Neonatal Unit Discharge, and at 60 days PD
Secondary Urine biomarkers for bone health Urinary Ca, P and creatinine At Baseline (if possible), pre-FEF Day 1, then weekly pre-FEF Days 7, 14, etc. and FEF Day 1, then weekly on FEF Days 7, 14, 21, until Neonatal Unit Discharge, and at 60 days PD
Secondary Vitamin D Vitamin D FEF Day 1, Neonatal Unit Discharge and at 60 days PD
Secondary Fecal microbiota Fecal microbiota composition, diversity and metabolism markers (SCFAs) Baseline, FEF Day 1, then weekly on FEF Days 7, 14, 21, until Neonatal Unit Discharge, at 30 day-PD and 60 days PD
Secondary Fecal markers for gut health / maturation and immune status Fecal levels of calprotectin, alpha 1 antitrypsin, pancreatic elastase (i.e. chymotrypsin-like elastase family, member 3B (CELA3B)), Human beta-defensin 2 (HBD2) and secretory IgA Baseline (if feasible), FEF Day 1, Day 21, Neonatal Unit Discharge, 30 day-PD and 60 day-PD
Secondary Urine markers for gut health / maturation and immune status Urinary level (spot urine sample) of intestinal fatty acid binding protein (iFABP) Baseline (if feasible), FEF Day 1, Day 21, Neonatal Unit Discharge, 30 day-PD and 60 day-PD
Secondary AE reporting Number of AEs through investigator-confirmed AE reporting From the time the mother has consented to the infant's participation in the study until the 60 days PD visit
Secondary Bayley-III scores Bayley scales of Infants and Toddler development - 3rd edition At 12, 18, and 24 months
Secondary Developmental Milestone scores Parent-reported achievements of specific-age appropriate milestones (yes/no reponses to child performing specific milestones or not) At 12, 18, and 24 months
Secondary Child temperament scores Parent-reported child temperament questionnaire At 12, 18, and 24 months
Secondary Number of healthcare usage Retrospective paret-reported recall of the number of healthcare usage and hospitalizations At 12, 18, and 24 months
Secondary Feeding patterns Feeding practice outcomes collected retrospectively at each visit via a parent-reported questionnaire related to breastfeeding duration, prevalence of formula feeding, and age at initiation of complementary feeding At 12, 18, and 24 months